Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: A population-based case-control study
Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: A population-based case-control study
复制标题
DOI：
10.1002/ijc.22796
复制
发表时间：
2007-09-15
影响因子：
6.4
通讯作者：
Brenner, Hermann
中科院分区：
文献类型：
--
作者：
Hoffmeister, Michael;Chang-Claude, Jenny;Brenner, Hermann
最近的研究引起了人们对他汀类药物对结直肠癌 (CRC) 的保护作用以及与其他药物可能的联合作用的关注。由于他汀类药物通常与低剂量阿司匹林联合用药来预防心血管疾病，因此我们研究的目的是调查他汀类药物和低剂量阿司匹林对结直肠癌风险的单独和联合作用。我们在德国进行的一项基于人群的病例对照研究中，评估了 540 例经组织学证实的 CRC 病例和 614 例对照受试者的他汀类药物和低剂量阿司匹林的使用情况。多元逻辑回归。用于评估定期使用低剂量阿司匹林或他汀类药物以及两种药物联合使用对结直肠癌风险的影响。我们发现定期使用低剂量阿司匹林可适度降低结直肠癌风险（调整后比值比 0.77，95% 置信区间 0.551.07），并且与定期使用他汀类药物（OR 0.65，95% CI 0.43-0.99）或同时使用两种药物（OR 0.63，95% CI 0.36-1.10）有更强的相关性。联合使用小剂量阿司匹林和他汀类药物可使 5 年后风险降低 62%（OR 0.38，95% CI 0.15-0.97）。使用低剂量阿司匹林和他汀类药物的联合化学预防可能比任何一种单一药物在使用至少 5 年后提供更强的风险降低效果，但需要进一步证实，最好是在前瞻性队列研究中，并最终通过随机对照试验进行证实。 (c) 2007 年 Wiley-Liss, Inc.
Recent research has drawn attention to protective effects of statins on colorectal cancer (CRC) and possible joint effects with other drugs. Because statins are often administered in combination With low-dose aspirin for the prevention of cardiovascular disease, the aim of our study was to investigate individual and combined effects of statins and low-dose aspirin on CRC risk. We assessed use of statins and low-dose aspirin in 540 cases with histologically confirmed incident CRC and 614 control subjects in a populations based case-control study in Germany. Multiple logistic regression. was used to estimate the impact of regular use of either low-dose aspirin or statins, and of both drugs combined on CRC risk. We found modest risk reduction of CRC for regular use of low-dose aspirin (adjusted odds ratio 0.77, 95% confidence interval 0.551.07) and a stronger association with regular use of statins (OR 0.65, 95% CI 0.43-0.99) or use of both drugs (OR 0.63, 95% CI 0.36-1.10). Combined use of low-dose aspirin and statins was associated with risk reduction by 62% after 5 or more years (OR 0.38, 95% CI 0.15-0.97). Combinational chemoprevention with low-dose aspirin and statins might provide stronger risk reduction than either of the single drugs after at least 5 years use, but confirmation is needed, preferably in prospective cohort studies and eventually by randomized controlled trials. (c) 2007 Wiley-Liss, Inc.